21:33 , Jan 6, 2017 |  BC Week In Review  |  Company News

CymaBay, Kowa deal

CymaBay granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa rights in the U.S. to arhalofenate. CymaBay will receive $5 million up front and $10 million in near-term milestones, including the start of a planned...
01:43 , Jan 4, 2017 |  BC Extra  |  Company News

CymaBay grants Kowa U.S. rights to gout candidate

CymaBay Therapeutics Inc. (NASDAQ:CBAY) granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa Co. Ltd. (Nagoya, Japan) rights in the U.S. to arhalofenate ( MBX-102 ), which is in development to treat gout. CymaBay announced...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Arhalofenate: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 239 patients with gout, hyperuricemia and a history of >=3 flares in the last 12 months showed that 800 mg once-daily oral arhalofenate met the...
03:03 , Feb 25, 2015 |  BC Extra  |  Clinical News

CymaBay falls on Phase IIb gout data

CymaBay Therapeutics Inc. (NASDAQ:CBAY) fell $2.27 (19%) to $9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate ( MBX-102 ) to treat gout. While the trial met its primary endpoint...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Arhalofenate: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 32 patients with gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate plus 40 mg febuxostat and 20%,...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Arhalofenate: Completed Phase IIb enrollment

CymaBay completed enrollment of >225 patients in a double-blind, placebo-controlled, international Phase IIb trial comparing 600 and 800 mg oral arhalofenate once daily vs. 300 mg oral allopurinol once daily with or without 0.6 mg...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a...
00:45 , Jul 23, 2014 |  BC Extra  |  Financial News

CymaBay raises $22 million in follow-on

CymaBay Therapeutics Inc. (NASDAQ:CBAY) raised $22 million through the sale of 4 million shares at $5.50 in a follow-on underwritten by Cowen; Stifel; Roth Capital Partners; and National Securities. CymaBay's arhalofenate ( MBX-102 ) is...
07:00 , Jul 21, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

REGULATORY MILESTONES Basilea Pharmaceutica AG (SIX:BSLN) was up CHF0.35 to CHF97.90 last week after submitting an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (zygomycosis). Partner Astellas Pharma Inc. (Tokyo:4503) submitted...